Our data revealed a significant difference in DMFS between high-risk and low-risk groups as defined by our prognostic model, illustrating that our model can discriminate patients at low risk and high risk of distant metastasis in HR−/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.